Tapping into traditional healing

Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

PDF of article

Goodness Growth Holdings Appoints Josh Rosen to Board of Directors

VIEW ALL NEWS

Goodness Growth Holdings Announces Second Quarter 2021 Financial Results

– Q2 GAAP revenue of $14.2 million increased 16% compared to Q2 2020 –
– Excluding former PA and OH subsidiaries, Q2 revenue increased 45% YoY and 8% sequentially –
– Record GAAP gross profit margin of 49% reflects greater scale and improving efficiency of operations –

MINNEAPOLIS, Aug. 13, 2021 /PRNewswire/ — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today reported financial results for its second quarter ended June 30, 2021. All currency figures referenced in this press release reflect U.S. dollar amounts.

Goodness Growth Holdings (CSE: GDNS; OTCQX: GDNSF) is the new parent company of Vireo Health and Green Goods. (PRNewsfoto/Goodness Growth Holdings)

“Our second quarter performance was in line with our expectations, and we were pleased to see increased scale and efficiency of operations contribute to record gross margin performance during the quarter,” said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. “As we discussed on last quarter’s call, our wholesale performance in Maryland was temporarily impacted by the move to our recently completed state-of-the-art manufacturing facility, and we expect to see that facility reach normalized production levels during the third quarter of this year. Additionally, our expansion projects in New Mexico and Arizona will help strengthen revenue and profitability in the second half of this year, especially in the fourth quarter when the expansion projects are operating at full capacity.”

Dr. Kingsley continued, “Our operating teams are focused on flower production, strain variety and quality in all of our markets, and we’re continuing to make progress on our expansion plans in New York and we will share updates on these plans throughout the year. As a reminder, the recent passage of adult-use legislation in New York and New Mexico and the inclusion of flower to Minnesota’s medical program have substantially improved our long-term outlook in each of these markets.”

Summary of Key Financial Metrics

Three Months Ended

Six Months Ended

US $ in millions

June 30,

June 30,

2021

2020

Variance

2021

2020

Variance

GAAP Revenue

$14.2

$12.2

16.5%

$27.4

$24.3

12.7%

Revenue (excl. former PA and OH subsidiaries)

$14.2

$9.8

44.5%

$27.4

$19.8

38.0%

GAAP Gross Profit

$6.9

$3.6

92.5%

$12.5

$6.9

82.4%

Gross Profit Margin

48.6%

29.4%

1,920 bps

45.7%

28.2%

1,750 bps

SG&A Expenses

$8.3

$6.3

32.1%

$16.3

$13.2

24.1%

SG&A Expenses (% of Sales)

58.3%

51.4%

690 bps

59.6%

54.1%

550 bps

Adjusted EBITDA (non-GAAP)

($1.0)

($1.8)

NM

($2.7)

($4.9)

NM

Adjusted EBITDA Margin (non-GAAP)

(6.8%)

(14.5%)

770 bps

(10.0%)

(20.1%)

1,010 bps

Second Quarter Business Highlights

  • Total revenue of $14.2 million increased 16.5 percent year-over-year. Excluding results from the Company’s former subsidiaries in Pennsylvania, revenue increased 44.5 percent compared to Q2 2020.
  • Gross profit increased by $3.3 million to $6.9 million, or 48.6 percent of sales as compared to $3.6 million, or 29.4 percent of sales in Q2 2020.
  • During the quarter, the Company completed the planned expansion of its cultivation and processing facility in New Mexico, which is now fully operational. The Company now has four operating dispensaries and 13,000 sq. ft. of cultivation capacity in the New Mexico market, which is expected to transition to adult-use sales in the spring of calendar year 2022, pending development of operating regulations.
  • During the quarter, the Company announced the launch of its ground medical cannabis flower products in the state of New York. The ground flower line is being sold in 3.5-gram and 7-gram jars and will be expanded to feature indica, sativa, and hybrid strains such as Killer Kush, Wedding Cake, and a Kosher-approved Tangie Kush. These products will be available at all four of the Company’s dispensaries in New York and via home delivery.
  • On June 8-9, 2021, the Company hosted its inaugural Investor Day events, during which the Company discussed the long-term outlook for its various state markets and also announced that its subsidiary, Resurgent Biosciences, plans to expand its research into psychedelics. Resurgent is a non-plant/fungus touching-entity and does not intend to engage directly in the cultivation, manufacture, or distribution of any psychedelics. For more information regarding the Company’s Investor Day events and disclosures, please visit https://goodnessgrowth2021.q4ir.com.

Second Quarter Financial Summary

Total revenue was $14.2 million in the first quarter, an increase of 16.5 percent as compared to Q2 2020, including the Company’s former subsidiaries in Pennsylvania and Ohio. Excluding contributions from Pennsylvania and Ohio, revenue increased 44.5 percent. Retail revenue excluding Pennsylvania increased 35.7 percent to $11.3 million in Q2 2021 and reflected growth in each of the Company’s retail markets. Wholesale revenue, excluding Pennsylvania and Ohio increased by 92.1 percent to $2.9 million, driven by strong growth in Arizona and New York.

Gross profit was $6.9 million, or 48.6 percent of revenue, as compared to gross profit of $3.6 million or 29.4 percent of revenue in Q2 last year. The improvement in gross profit was driven by higher throughput across all markets resulting in decreased fixed cost per unit.

Total operating expenses in the second quarter were $10.2 million, a reduction of $5.5 million as compared to $15.6 million in the second quarter of 2020. The decrease in total expenses was attributable to a decrease in stock- based compensation expenses, partially offset by increased general and administrative expenses which was driven by operational buildouts in Arizona and Maryland, where the Company is in the process of completing large cultivation and manufacturing expansion projects.

Total other expenses were $1.3 million during Q2 2021, a reduction of $2.4 million compared to $3.7 million in Q2 2020. The decrease was primarily attributable to a gain on derivative liability of $1.5 million during the quarter.

EBITDA, as described in accompanying disclosures and footnotes, was a loss of $0.9 million during Q2 2021, compared to a loss of $13.2 million in Q2 2020. Adjusted EBITDA was a loss of $1.0 million in Q2 2021, as compared to a loss of $1.8 million in Q2 2020. Please refer to the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this press release for additional information.

Net loss in Q2 2021 was $5.5 million, as compared to a net loss of $16.1 million in Q2 2020. The improvement in net loss was driven by the increase in gross profit margin and lower operating and other expenses, partially offset by increased income tax expense.

Other Events

On July 9, 2021, the Company announced that its subsidiary has signed a definitive agreement to purchase a medical cannabis dispensary located in Baltimore. Upon closing of the transaction, which is expected to occur later this year pending regulatory approval and subject to customary closing conditions, the Company will have two dispensaries operating in the state of Maryland.

On August 13, 2021, the Company announced in a separate news release that it had appointed Josh Rosen to its Board of Directors, expanding its number of board seats to seven. Josh Rosen is Managing Partner at Bengal Capital, and former Chief Executive Officer and Chairman of 4Front Ventures, a multi-state U.S. cannabis operator.

Balance Sheet and Liquidity

As of June 30, 2021, the Company had 126,021,801 equity shares issued and outstanding on an as-converted basis, and 154,346,560 shares outstanding on an as-converted, fully diluted basis.

As of June 30, 2021, total current assets were $42.0 million, including cash on hand of $20.8 million. Total current liabilities were $16.1 million, with $1.1 million in debt due within 12 months.

Horizon Strategy & Outlook

The Company’s Horizon strategy was unveiled during its recent Investor Day events, and is a plan for growth through fiscal year 2022. Over this timeframe, the Company expects to open an additional 6-10 Green Goods® retail dispensaries, and a majority of the Company’s markets are expected to begin to generate more substantial revenue growth as pending changes to regulatory regimes take effect.

Management has provided various outlook ranges for performance in fiscal year 2022, the achievement of which depend upon the Company’s ability to achieve expected biomass production yields, the timing of completion of various development projects, the timing of commencement of adult-use sales in New Mexico and New York, and the timing of commencement of flower sales in the Minnesota medical market.

Dr. Kingsley commented, “We believe the expansion projects we have underway, combined with growth catalysts driven by changing regulatory frameworks in our markets, will result in substantial improvements in revenue growth and profitability over the next 18 months. Variability in our performance will depend on the timing of completion of projects and regulatory approvals in our markets, but we believe we’re positioned for significant growth next year as we continue executing our Horizon strategy.”

Conference Call and Webcast Information

Goodness Growth management will host a conference call with research analysts today, Friday, August 13, 2021 at 8:00 a.m. ET (7:00 a.m. CT) to discuss its financial results for its second quarter ended June 30, 2021. Interested parties may register to attend the conference call via the following link: http://www.directeventreg.com/registration/event/9694714.

Upon registration, each participant will be provided with call details and a registrant ID for Goodness Growth’s conference ID number 9694714. A live audio webcast of this event will also be available in the Events & Presentations section of the Company’s Investor Relations website and will be archived for one year.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company’s operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites, and distributes its products through its growing network of Green Goods® and other retail locations and third-party dispensaries. Its team of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com.

Additional Information

Additional information relating to the Company’s second quarter 2021 results will be available on EDGAR and SEDAR later today. Goodness Growth refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, one-time transactions, and other non-recurring non-cash items. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@goodnessgrowth.com 

albezakes@goodnessgrowth.com 

(612) 314-8995

(267) 221-4800

Forward-Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “expect,” “plans,” “strategy,” “outlook,” “will,” “believe,” “continue,” “range,” “subject to,” and “pending,” or variations of such words and phrases. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue and cash on hand may differ materially from the revenue and cash values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to the timing of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to cannabis operations in the United States and any changes to such laws; operational, regulatory and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; and risk factors set out in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

Supplemental Information

The financial information reported in this news release is based on audited financial statements for the fiscal year ended December 31, 2020 and unaudited condensed interim consolidated financial statements for the fiscal quarter ended June 30, 2021. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2021 AND DECEMBER 31, 2020

(Amounts Expressed in United States Dollars, Except for Share Amounts, unaudited and condensed)

June 30, 

December 31, 

2021

2020

Assets

Current assets:

Cash

$

20,826,356

$

25,513,180

Restricted cash

1,592,500

Accounts receivable, net of allowance for doubtful accounts of $257,729 and $132,490, respectively

2,444,967

696,994

Inventory

16,727,640

12,644,895

Prepayments and other current assets

1,863,841

1,552,278

Notes receivable

100,561

293,700

Deferred acquisition costs

28,136

Assets Held for Sale

4,596,445

Deferred financing costs

120,266

Total current assets

41,963,365

47,038,394

Property and equipment, net

42,104,121

30,566,259

Operating lease, right-of-use asset

8,762,777

8,163,844

Notes receivable, long-term

3,750,000

3,750,000

Intangible assets, net

11,181,670

8,409,419

Goodwill

3,132,491

3,132,491

Deposits

1,413,719

1,412,124

Deferred tax assets

367,000

157,000

Total assets

$

112,675,143

$

102,629,531

Liabilities

Current liabilities

Accounts Payable and Accrued liabilities

10,012,597

13,477,303

Right of use liability

1,284,248

857,294

Convertible notes, net of issuance costs

900,000

Long-Term debt, current portion

1,110,000

1,110,000

Liabilities held for sale

3,595,301

Warrant Liability

3,705,859

Total current liabilities

16,112,704

19,939,898

Right-of-use liability

21,787,039

20,343,063

Long-Term debt

18,533,128

Total liabilities

$

56,432,871

$

40,282,961

Stockholders’ equity

Subordinate Voting Shares ($- par value, unlimited shares authorized; 72,660,602 shares issued and outstanding)

Multiple Voting Shares ($- par value, unlimited shares authorized; 459,950 shares issued and outstanding)

Super Voting Shares ($- par value; unlimited shares authorized; 65,411 shares issued and outstanding, respectively)

Additional Paid in Capital

170,442,492

164,079,614

Accumulated deficit

(114,200,220)

(101,733,044)

Total stockholders’ equity

$

56,242,272

$

62,346,570

Total liabilities and stockholders’ equity

$

112,675,143

$

102,629,531

 

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

(Amounts Expressed in United States Dollars, Except for Share Amounts, unaudited and condensed)

Three Months Ended June 30,

Six Months Ended June 30,

2021

2020

2021

2020

Revenue

$

14,230,900

$

12,215,365

$

27,420,789

$

24,333,932

Cost of sales

Product costs

7,273,011

8,430,507

14,779,059

17,132,160

Inventory valuation adjustments

45,000

194,234

113,000

333,242

Gross profit

6,912,889

3,590,624

12,528,730

6,868,530

Operating expenses:

Selling, general and administrative

8,299,682

6,283,343

16,335,673

13,160,468

Stock-based compensation expenses

1,408,080

8,985,422

3,722,655

11,721,360

Depreciation

246,247

219,662

417,809

222,628

Amortization

206,442

154,191

412,885

308,381

Total operating expenses

10,160,451

15,642,618

20,889,022

25,412,837

Loss from operations

(3,247,562)

(12,051,994)

(8,360,292)

(18,544,307)

Other income (expense):

Gain on disposal of assets held for sale

437,107

Derivative gain (loss)

1,531,371

(2,292,130)

1,689,900

(966,202)

Interest expenses, net

(2,756,358)

(1,543,169)

(3,782,504)

(2,993,433)

Other income (expenses)

(98,055)

141,859

(41,387)

(327,413)

   Other expenses, net

(1,323,042)

(3,693,440)

(1,696,884)

(4,287,048)

Loss before income taxes

(4,570,604)

(15,745,434)

(10,057,176)

(22,831,355)

Current income tax expenses

(885,000)

(346,900)

(2,620,000)

(852,000)

Deferred income tax recoveries

$

(25,000)

$

(23,000)

$

210,000

$

55,000

Net loss and comprehensive loss

(5,480,604)

(16,115,334)

(12,467,176)

(23,628,355)

Net loss per share – basic and diluted

($0.04)

($0.16)

($0.10)

($0.25)

Weighted average shares used in computation of net loss per share – basic and diluted

125,557,734

98,871,038

120,856,801

93,695,441

 

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

SIX MONTHS ENDED JUNE 30, 2021 AND 2020

Six Months Ended June 30,

(Amounts expressed in USD, except for share amounts, unaudited and condensed)

2021

2020

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

$

(12,467,176)

$

(23,628,355)

Adjustments to reconcile net loss to net cash used in operating activities:

Inventory valuation adjustments

113,000

333,242

Depreciation

417,809

222,628

Depreciation capitalized into inventory

986,896

1,057,849

Non-cash operating lease expense

519,176

624,625

Amortization of intangible assets

412,885

308,381

Stock-based payments

3,722,655

11,721,360

Interest Expense

886,628

Gain/loss

53,077

Deferred income tax

(210,000)

(1,103,100)

Accretion

195,197

348,382

Derivative (Gain) Loss

(1,689,900)

966,202

Gain on disposal of OMS

(437,107)

Change in operating assets and liabilities:

Accounts Receivable

(1,531,985)

128,106

Prepaid expenses

(292,260)

525,028

Inventory

(4,059,044)

(516,787)

Accounts payable and accrued liabilities

(4,182,954)

1,838,680

Change in assets and liabilities held for sale

124,843

(369,485)

Net cash used in operating activities

$

(17,491,337)

$

(7,490,167)

CASH FLOWS FROM INVESTING ACTIVITIES:

PP&E Additions

$

(11,028,976)

$

(1,402,085)

Proceeds from sale of OMS net of cash

1,150,000

Deposits

(1,595)

16,265

Net cash provided by (used in) investing activities

$

(9,880,571)

$

(1,385,820)

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from issuance of shares

$

$

7,613,490

Deferred financing costs

(865,769)

Proceeds from long-term debt

24,028,295

Convertible debt payment

(900,000)

Proceeds from option exercises

1,075,723

Lease payments

(653,165)

(652,477)

Net cash provided by financing activities

$

22,685,084

$

6,961,013

Net change in cash and restricted cash

$

(4,686,824)

$

(1,914,974)

Cash and restricted cash, beginning of period

$

25,513,180

$

9,234,173

Cash and restricted cash, end of period

$

20,826,356

$

7,319,199

Reconciliation of Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non- GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

Three Months Ended 

Six Months Ended 

June 30, 

June 30, 

2021

2020

2021

2020

Net income (loss)

$

(5,480,604)

$

(16,115,334)

$

(12,467,176)

$

(23,628,355)

Interest expense, net

2,756,358

1,543,169

3,782,504

2,993,433

Income taxes

910,000

369,900

2,410,000

797,000

Depreciation & Amortization

452,689

373,853

830,694

531,009

Depreciation included in cost of goods sold

478,537

582,946

986,896

1,057,849

EBITDA (non-GAAP)

$

(883,020)

$

(13,245,466)

$

(4,457,082)

$

(18,249,064)

Derivative Gain

(1,531,371)

2,292,130

(1,689,900)

966,202

Inventory adjustment

45,000

194,234

113,000

333,242

Share-based compensation

1,408,080

8,985,422

3,722,655

11,721,360

Severance Expense

339,997

Gain on sale of discontinued operations

(437,107)

Adjusted EBITDA (non-GAAP)

$

(961,311)

$

(1,773,680)

$

(2,748,434)

$

(4,888,263)

 

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/goodness-growth-holdings-announces-second-quarter-2021-financial-results-301354867.html

SOURCE Goodness Growth Holdings, Inc.

Goodness Growth Holdings to Report Second Quarter Results on August 13, 2021

MINNEAPOLIS, July 29, 2021  /PRNewswire/ — Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that it will report financial results for its second quarter ended June 30, 2021 on Friday, August 13, 2021 before the market opens.

Goodness Growth Holdings (CSE: GDNS; OTCQX: GDNSF) is the new parent company of Vireo Health and Green Goods. (PRNewsfoto/Goodness Growth Holdings)

The Company will hold a conference call and webcast to discuss its business and financial results that same day at 8:00 a.m. Eastern Time (7:00 a.m. Central Time). Interested parties may register to attend the call via this link: http://www.directeventreg.com/registration/event/9694714.

Upon registration, each participant will be provided with call details and a registrant ID for Goodness Growth’s conference ID number 9694714. A live audio webcast of the call will also be available in the Events & Presentations section of the Company’s investor relations website. A webcast replay will be made available for one year on the Company’s website.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company’s operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities and state-of-the-art cultivation sites, and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 18 dispensaries across the United States. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com.

Contact Information

Investor Inquiries:
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com 
(612) 314-8995

Media Inquiries:
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com  
(267) 221-4800

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/goodness-growth-holdings-to-report-second-quarter-results-on-august-13-2021-301344063.html

SOURCE Goodness Growth Holdings

Goodness Growth Holdings Signs Definitive Agreement to Acquire Charm City Medicus Dispensary in Baltimore, Maryland

VIEW ALL NEWS

Goodness Growth Holdings Subsidiary Resurgent Biosciences Files Patent for Virtual Reality Applications to Facilitate Therapeutic Psychedelic Experiences

VIEW ALL NEWS

Goodness Growth Holdings Subsidiary Resurgent Biosciences Announces Planned Expansion into Psychedelics Research and IP Development

– Non-plant touching, ancillary focus will leverage proven expertise of medical and scientific research teams –

– Company also announces launch of B-2-B website for its TerpSafe™ packaging technology –

– Management to host conference call with investment community today at 8:30 a.m. ET –

MINNEAPOLIS – June 9, 2021 – Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences (“Resurgent”), plans to expand its intellectual property development and clinical research efforts into psychedelic medicine. Resurgent is a non-plant/fungus touching-entity and does not intend to engage directly in the cultivation, manufacture, or distribution of any psychedelics.

“Our formation of Resurgent Biosciences was a strategic move to separate our multi-state cannabis company from the non-plant-touching, ancillary business opportunities within our intellectual property portfolio,” said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. “Resurgent has proven its ability to conduct clinical research of medicinal plants in partnership with leading hospitals across the United States, and we have also made substantial progress to commercialize several of the technological innovations in our IP portfolio, including our patent-pending TerpSafe™ packaging technology and multi-channel vaporizer.”

Kingsley continued, “Resurgent’s expansion into psychedelics represents a natural extension of our team’s medical and scientific expertise, and frankly, we believe the opportunities for psychedelics to transform the future of mental health and psychiatry are far too significant for us to ignore. We believe the formation of clinical research partnerships to prove efficacy of psychedelic therapies, and the pursuit of novel technologies and applications which could make psychedelic medicine more accessible and affordable for patients and healthcare providers, could drive substantial value creation for our shareholders in the future.”

Launch of TerpSafe™ Technology to Broader Markets

 

The Company also announced the launch of its TerpSafe™ packaging technology to broader cannabis markets across North America. TerpSafe™ packaging was designed for consumers who demand ultimate freshness of cannabis flower, and its technology has been proven to preserve 100 percent of the terpene content of flower for more than six weeks, compared to a control group which lost more than 30 percent of terpene content within four weeks of packaging.

TerpSafe™ packaging represents the first commercialized product available for sale from the Resurgent Biosciences IP portfolio, and it is being manufactured and distributed under a licensing agreement with eBottles420, the largest supplier of cannabis packaging in North America. This novel packaging technology is now available in the Company’s cannabis markets in Arizona and Maryland under the Amplifi™ brand of flower and will soon be expanding to additional markets nationwide. Interested parties who would like to learn more about TerpSafe™ packaging are encouraged to visit https://tryterpsafe.com.

 

2021 Investor Day Conference Call and Webcast

Later today, Goodness Growth Holdings management will host a live conference call and webcast with the investment community to discuss these updates in conjunction with its 2021 Investor Day events. All interested parties are invited to join by registering in advance using the registration links contained in this news release. Webcast replays of these events will also be posted to the Company’s Investor Day page of its corporate website at www.goodnessgrowth.com.

2021 Investor Day Conference Call and Webcast

Date: Wednesday, June 9, 2021

Time: 8:30 a.m. Eastern Time

Conference Call Registration: http://www.directeventreg.com/registration/event/2871533

Webcast Registration:

https://event.on24.com/wcc/r/3192578/ECC0B9E645DB41B7F86E92F94DD4BEB3

 

About Goodness Growth Holdings, Inc.

 

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company’s operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities, state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 16 dispensaries across the United States. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com.

 

Contact Information

Investor Inquiries:

Sam Gibbons

Vice President, Investor Relations

samgibbons@vireohealth.com

(612) 314-8995

 

 

Media Inquiries:

Albe Zakes

Vice President, Corporate Communications

albezakes@vireohealth.com
(267) 221-4800

Forward-Looking Statement Disclosure

 

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “planned,” “plans,” “believe,” “pursuit,” “could,” “strategic,” “will,” “would,” “future,” “expect,” “potential,” or variations of such words and phrases. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue and cash on hand may differ materially from the revenue and cash values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to the timing of adult-use legislation and operating frameworks in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to cannabis operations in the United States and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; and risk factors set out in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

Vireo Health Announces Name Change to Goodness Growth Holdings in Conjunction with 2021 Investor Day Events

– Management unveils its Horizon Strategy with outlook ranges for FY22 revenue and adjusted EBITDA –
– Company to host video webcast tonight at 4:00pm ET followed by conference call tomorrow morning –
– Company to begin trading as Goodness Growth Holdings in the U.S. and Canada tomorrow –

MINNEAPOLIS, June 8, 2021 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), the leading physician-led, science-focused multi-state cannabis company, today announced a series of corporate updates in conjunction with its 2021 Investor Day events. In addition to unveiling its Horizon Strategy and outlook ranges for FY22 revenue and adjusted EBITDA performance, the Company also announced that effective June 9, 2021 at market open, its subordinate voting shares will begin trading as Goodness Growth Holdings, Inc., under the ticker symbol “GDNS” on the Canadian Securities Exchange (CSE: GDNS) and on the OTCQX Market in the United States under ticker symbol “GDNSF” (OTCQX: GDNSF).

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

“Our evolution to Goodness Growth reflects the progression of our business from a predominantly early-stage, medical-market operator to one of the strongest organic growth generators across recreational-use and medical cannabis markets in the United States,” said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. “Vireo always has been and will continue to be a flagship brand of medical products, but this holding company model reflects a much more expansive view of our future and clearly differentiates our plant-touching assets from our science and IP incubator, Resurgent Biosciences.”

The Horizon Strategy and FY22 Outlook

The Company’s Horizon strategy is a plan for growth through fiscal year 2022, a period in which a majority of the Company’s markets are expected to begin to generate more substantial revenue growth as currently pending changes to regulatory regimes take effect. Over this timeframe, the Company expects to open an additional 6-10 Green Goods™ retail dispensaries. Management also provided several additional outlook updates in conjunction with this strategy, which are subject to the on-time completion of various development projects, commencement of adult-use sales in New Mexico beginning in Q1 of 2022, commencement of adult-use sales in New York in the summer of 2022, and the commencement of flower sales in the Minnesota medical market in the spring of 2022.

  • The Company expects to generate total revenue in the range of $140 to $180 million in FY22
  • The Company expects to generate adjusted EBITDA in the range of $35 to $55 million in FY22
  • Management reminds investors that the Company had approximately $40 million in cash on its balance sheet as of March 31, 2021
  • Management expects net capex, excluding financing from real estate partners, to be in the range of approximately $15 to $20 million over this planning horizon
  • The Company expects to begin generating positive cash flow from operations during 1H22

Dr. Kingsley continued, “We expect that recent growth investments we’ve made, combined with the expansion projects we have planned, and growth catalysts driven by changing regulatory frameworks will result in substantial improvements in revenue growth and profitability over the next 18 months. We expect to support this more than tripling of our revenue through an increase of more than 300 percent in biomass production capacity as we execute the Horizon strategy and are pleased to be showcasing the potential of our asset portfolio to investors at our investor day events later tonight and tomorrow morning.”

2021 Investor Day Event Information

Tonight’s pre-recorded video webcast will introduce investors to the Goodness Growth Holdings vision, mission, and management team, and examine critical components of the Horizon strategy in more detail. The video will also allow investors to experience the Company’s new Green Goods™ retail dispensaries, visit several of the Company’s largest manufacturing facilities, and showcase the various expansion projects that are currently underway.

Tomorrow morning’s live conference call and webcast presentation will complement the video component of the Company’s Investor Day events and enable members of the investment community to engage directly with management and ask questions. Both of these virtual events will be webcast live from the Investor Day section of the Company’s website at www.goodnessgrowth.com, and all interested parties may also join by registering in advance using the registration links contained in this news release.

2021 Investor Day Video Webcast
Date:    Tuesday, June 8, 2021
Time:   4:00 p.m. Eastern Time
Webcast Registration:
https://event.on24.com/wcc/r/3192578/ECC0B9E645DB41B7F86E92F94DD4BEB3

2021 Investor Day Conference Call and Webcast
Date:    Wednesday, June 9, 2021
Time:   8:30 a.m. Eastern Time
Conference Call Registration: http://www.directeventreg.com/registration/event/2871533
Webcast Registration:
https://event.on24.com/wcc/r/3192578/ECC0B9E645DB41B7F86E92F94DD4BEB3

Webcast replays of these events will be posted to the Investor Day section of the Company’s website at www.goodnessgrowth.com and will be available online for a period of one year.

About Vireo Health International, Inc.

Vireo Health International, Inc. is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally friendly facilities, state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Vireo’s team of more than 450 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow,  process, and/or distribute cannabis in eight markets and operates 16 dispensaries nationwide. For more information about Vireo Health, please visit www.vireohealth.com.

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons 

Albe Zakes

Vice President, Investor Relations 

Vice President, Corporate Communications

samgibbons@vireohealth.com 

albezakes@vireohealth.com  

(612) 314-8995 

(267) 221-4800

Forward-Looking Statement Disclosure

This press release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “strategy,” “outlook,” “range,” “will,” “view,” “future,” “plan,” “expected,” “pending,” “expects,” “planned,” “potential,” or variations of such words and phrases.  These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue and cash on hand may differ materially from the revenue and cash values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to the timing of adult-use legislation and operating frameworks in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to cannabis operations in the United States and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; and risk factors set out in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-announces-name-change-to-goodness-growth-holdings-in-conjunction-with-2021-investor-day-events-301307831.html

SOURCE Vireo Health International, Inc.

Statement from Vireo Health on the Expansion of Minnesota’s Medical Cannabis Program to Include the Use of Smokable Cannabis Flower

VIEW ALL NEWS

Vireo Health to Host Virtual Investor Day Events on June 8th and June 9t

MINNEAPOLIS, May 19, 2021 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), the leading physician-led, science-focused multi-state cannabis company, today announced that it will host a series of online virtual events for the institutional and retail investment communities on Tuesday, June 8, 2021 and Wednesday, June 9, 2021.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

On the evening of Tuesday, June 8, 2021, Vireo will host an online video webcast featuring the Company’s executive leadership team and provide updates regarding its long-term vision, strategy, and financial outlook. In addition to the online video webcast, members of Vireo’s senior leadership team will host a conference call the following morning to discuss these business updates and answer questions from the investment community.

“We’re looking forward to providing the investment community with a more detailed look at our portfolio of attractive U.S. cannabis assets and showcasing the potential of the various expansion projects that are currently underway across our operating footprint,” said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. “We would have liked to host this event in person with shareholders and analysts across the United States and Canada, but challenges related to the COVID-19 pandemic prevented us from welcoming all audiences in an in-person setting. Our video webcast and conference call will enable audiences to experience Vireo in an exciting format and we look forward to welcoming everyone in June.”

Vireo’s virtual investor day events will be webcast live and all interested parties are invited to join by registering in advance using the registration links contained in this news release.

Vireo Health Virtual Investor Day Video Webcast
Date:    Tuesday, June 8, 2021
Time:   4:00 p.m. Eastern Time
Registration: https://event.on24.com/wcc/r/3192578/ECC0B9E645DB41B7F86E92F94DD4BEB3
Replay:   A replay will be posted to Vireo’s Investor Relations website

Vireo Health Investment Community Conference Call
Date:    Wednesday, June 9, 2021
Time:   8:30 a.m. Eastern Time
Registration: http://www.directeventreg.com/registration/event/2871533
Replay: A replay will be posted to Vireo’s Investor Relations website

About Vireo Health International, Inc.

Vireo Health International, Inc. is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally friendly facilities, state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods™ and other retail locations and third-party dispensaries. Vireo’s team of more than 400 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow, process, and/or distribute cannabis in eight markets and operates 16 dispensaries nationwide. For more information about Vireo Health, please visit www.vireohealth.com.

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

samgibbons@vireohealth.com  

albezakes@vireohealth.com

(612) 314-8995

(267) 221-4800

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-to-host-virtual-investor-day-events-on-june-8th-and-june-9th-301294634.html

SOURCE Vireo Health International, Inc.